This is an old press release (over 1 year old) but I thought it of interest
because they will be using recombinant human lactoferrin to treat cancers,
asthma, infections, etc.
This pharmaceutical is based on research of human milk (particularly the
research done at Baylor College of Medicine). I believe the President of Baylor
College of Medicine is one of the advisors to this company. DSM (Dutch State
Mines) also makes the AA oil for Martek Bioscience through fermentation
processes. Interestingly, DSM use to be an oil company (but sold off this part of
the business). They do use hexane to extract the AA oil. Many of the BOD on
Agennix are ex-oil executives and Martek is a NASA spin-off company.
Fascinating that they are involved in making ingredients for infant formula and
pharmaceuticals. Anyway, it is ironic that they can sell a product based on human
milk research to treat these various health problems. Yet, if we, the
breastfeeding advocates, state that human milk kills cancer cells or prevents asthma, we
are considered radical and unscientific. (heaven forbid we say this publicly
because there is no proof) Yet, become a pharmaceutical company, state that
recombinant human lactoferrin can treat cancer , asthma, or warts then
"presto-chango" acceptance. (I do recognize this is a concentrated form of the human
milk component and it is more acceptable because it is fermented and gene-
spliced with some mold or bacteria) I sometimes think we are living in the most
crazy of times.
Valerie W. McClain, IBCLC
http://www5.dsm.com/en_US/html/media/press_releases/29-02-aggenix.htm
Agennix and DSM Pharmaceutical Products announce opening of recombinant human
lactoferrin manufacturing facility
Heerlen, NL / Houston (TX),USA,17-Sep-2002
Dedicated facility in Capua, Italy, operational
Agennix Inc. and DSM Pharmaceutical Products, a business group of DSM N.V.,
today jointly announced the opening of a new manufacturing facility on DSM’s
fermentation site in Capua, Italy.
The facility, located just north of Naples, is dedicated to the commercial
production of pharmaceutical grade recombinant human lactoferrin (rhLF). RhLF is
a protein found naturally in milk and other endocrine secretions that plays
an essential role in stimulating the body’s immune system to fight cancer and
infections, and protects against asthma and other allergic diseases.
"This project clearly reflects DSM's strategic choice to make further
investments in the Life Science industry in general and in biotechnology in
particular," said Henk Numan, President of DSM Pharmaceutical Products. “Fermentation
is one of DSM’s core technologies and is widely applied in a variety of
pharmaceuticals. The opening of the new facility is the reward for hard work by a
dedicated project team that worked in very close collaboration with Agennix. We
are proud of this success and we are looking forward to continuing the
excellent collaboration with Agennix.”
“We are very pleased with our collaboration with DSM Pharmaceutical Products,”
said Rick Barsky, Chief Executive Officer of Agennix. “The opening of this
facility is an important milestone in Agennix’s development of rhLF. It will
expand our manufacturing capacity from tens of kilos to tons
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
